Get in touch with one of our Xperts.
We are pleased to share that the CTNNB1 Foundation has received approval to initiate a Phase I/II clinical trial evaluating URBAGEN™, the first investigational gene-replacement therapy developed for CTNNB1 syndrome. This represents a significant step forward for the CTNNB1 community, as the first therapeutic program to reach human clinical testing for this rare neurodevelopmental condition. continue reading…
We are proud to have supported TAHO Pharmaceuticals Ltd. (TAHO) in the successful submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TAH3311, the first orodispersible film formulation of apixaban. This submission marks an important milestone for TAHO and a promising advancement in the field of anticoagulant therapy. TAH3311 has continue reading…
3D-PharmXchange is proud to be a partner in the BRECISE project (Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement), a five-year initiative co-funded by the Innovative Health Initiative (IHI) under Horizon Europe. The project brings together more than 30 public and private organizations across Europe with the shared goal of accelerating the continue reading…
3D-PharmXchange is proud to announce its collaboration with Antleron in the Living Factory 4.0 project. Antleron is a Leuven-based R&D company that develops custom bioprocess solutions for cell & gene therapy applications, with a focus on personalized and digital manufacturing. The Living Factory 4.0, supported by the CrossRoads program, aims to revolutionize the development and production of continue reading…
Empowering Dutch Biotech: Navigating Innovation and Market Success with the Dutch Regional Development Agencies on November 21, 2024 Ronald van der Geest, partner at 3D-PharmXchange, has been invited to attend the Life Sciences & Health ROMs Day, to advise the regional investment agencies on how to become even more effective in bringing Dutch Biotech ventures continue reading…
Inez de Greef elected as fellow of the Netherlands Academy of Engineering We are thrilled to announce that Inez de Greef, CEO of Treeway and co-founder and Managing Partner of 3D-PharmXchange, has been elected as a fellow of the Netherlands Academy of Engineering (NAE). The NAE brings together top experts in technological sciences and applied continue reading…
Knowledge for Growth, Europe’s leading conference in the field of life sciences, is set to take place in Antwerp, Belgium on June 1, 2023. This exceptional event will bring together the most influential individuals from the European life sciences community. Attendees will include key decision makers from the biotech, pharmaceutical, and MedTech industries, as well continue reading…
Fast-track drug development: taking the highway or the roundabout? In a race against time, costs and competitors, the pharmaceutical industry finds itself at a crossroads. As the world demands faster drug development, scientists embarking on product development are faced with a crucial decision: do we take the highway or the roundabout? Join us as we continue reading…
A successful drug development strategy is a well-designed and dynamic process. Making sure regulatory requirements are embedded from the start, is key. From pre-clinical all the way to registration, a well-organized set of action plans needs to be in place that guides and accelerates the client’s vision on how to support their targeted therapeutic area. continue reading…
3D-PharmXchange will be attending, exhibiting and/or presenting at the following conferences and events in 2023: Click on the event name for more information. Event Date(s) Location Exhibitor/Attendee World ADC March 13-16 London Attendee Bioprocessing Summit Europe March 14-16 Barcelona Attendee Dutch ATMP Summit March 15 Amsterdam Attendee DIA Europe March 22-24 Basel Attendee Innovation for continue reading…
© 3D-PharmXchange 2025